- Home
- SNES vs ALLR Comparison
SNES vs ALLR Comparison
Compare SNES & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- ALLR
- Stock Information
- Founded
- SNES 2004
- ALLR 2004
- Country
- SNES United States
- ALLR United States
- Employees
- SNES N/A
- ALLR N/A
- Industry
- SNES Agricultural Chemicals
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- SNES Industrials
- ALLR Health Care
- Exchange
- SNES Nasdaq
- ALLR Nasdaq
- Market Cap
- SNES 24.0M
- ALLR 20.2M
- IPO Year
- SNES 2016
- ALLR N/A
- Fundamental
- Price
- SNES $2.72
- ALLR $1.14
- Analyst Decision
- SNES Strong Buy
- ALLR Strong Buy
- Analyst Count
- SNES 1
- ALLR 1
- Target Price
- SNES $10.00
- ALLR $9.25
- AVG Volume (30 Days)
- SNES 78.6K
- ALLR 232.2K
- Earning Date
- SNES 11-10-2025
- ALLR 11-14-2025
- Dividend Yield
- SNES N/A
- ALLR N/A
- EPS Growth
- SNES N/A
- ALLR N/A
- EPS
- SNES N/A
- ALLR N/A
- Revenue
- SNES $2,301,000.00
- ALLR N/A
- Revenue This Year
- SNES $49.17
- ALLR N/A
- Revenue Next Year
- SNES $89.89
- ALLR N/A
- P/E Ratio
- SNES N/A
- ALLR N/A
- Revenue Growth
- SNES 39.37
- ALLR N/A
- 52 Week Low
- SNES $1.30
- ALLR $0.61
- 52 Week High
- SNES $6.24
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- SNES 32.29
- ALLR 36.06
- Support Level
- SNES $2.60
- ALLR $1.09
- Resistance Level
- SNES $3.40
- ALLR $1.32
- Average True Range (ATR)
- SNES 0.28
- ALLR 0.10
- MACD
- SNES -0.03
- ALLR -0.01
- Stochastic Oscillator
- SNES 16.85
- ALLR 10.53
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.